Optiscan Imaging Ltd (ASX:OIL)

Enabling "Real-time Virtual Biopsy" for Human Cancer Screening and Surgical Margin Detection

Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 11 June 2019.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (including OIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.

Notice

Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or connection with this presentation.

Corporate Snapshot

Board

Darren Lurie – Executive Chairman

B.LLB (Hons) and B.COM (Hons)

Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia). Darren is a former chair and non-executive director of ASX listed Farm Pride Foods Ltd (ASX:FRM).

Dr Philip Currie – Non Executive Director

MBBS (Hons), FRACP, MBA

Dr Currie is a leading cardiologist with more than 35 years experience in medical research, clinical cardiology and business. He completed his cardiology fellowship at the prestigious Mayo Clinic, staff cardiologist at both Mayo Clinic and Cleveland Clinic and was the Director of Echocardiography at Michigan Heart and Vascular Institute.

Graeme Mutton – Non Executive Director

CPA

Graeme is a long-standing shareholder in Optiscan and has a deep understanding of Optiscan`s technology and applications. He is a former manager of an accounting practice and successful business owner and operator.

Major Shareholders

- Peters Investments Pty Ltd: 10.0%
- Ibsen Pty Ltd: 9.9%

Total Securities on Issue

- 432,678,800 Ordinary Shares
- 2,600,000 Performance Rights
- 25,600,000 unlisted options

Market Capitalisation: $20million @4.7c

From Laboratory Benchtop to Operating Theatre

Desktop Confocal Microscope

Optiscan's confocal device

Successfully miniaturised high resolution benchtop confocal microscope into hand-held probe with 4.0mm diameter providing unique microscopic imaging for clinicians. Underpinned by multi-patented technology.

Commercial Focus

- Optiscan entering new commercial phase
- Sales of Carl Zeiss Meditec CONVIVO are expected in the first few months of FY20
- Optiscan is implementing plans to seek regulatory approvals for the sale of its own in human clinical device in multiple cancer applications
- FIVE2 (ViewnVivo) sales are anticipated in coming months in the United States, China and Australia with funding submissions to purchase the FIVE2 made by multiple institutions
- “Rental with Option to Buy” offered to institutions as alterative to straight purchase of the FIVE2
- Cost reduction focus has already saved in excess of $1.0m per annum

Optiscan Technology Enables "Real Time Virtual Biopsy"

Optiscan technology changing pathology and surgical cancer practice

- Screening, early cancer diagnosis and targeted biopsies
- Tumour margin detection in cancer surgery



Images available instantaneously compared to waiting 3-4 days for the return of pathology results

Cancer Cases Worldwide – Addressable Market

18.1M total cancer cases p.a.

297,000 Brain and CNS cancer cases p.a.

350,000 Lip and Oral cancer cases p.a.

570,000 Cervix& Uterus cancer cases p.a.

2.1M Breast cancer cases p.a.

3.4M Upper and Lower GI cancer cases p.a.

Carl Zeiss Meditec Collaboration

Application with Optiscan's Existing Probe Design (Seeking Regulatory Approval)

Flexible Endoscope Applications (Seeking Partner)

Sales opportunities for Optiscan devices exist for both cancer screening and in-surgery use.

In most applications, the number of screening procedures is many times the number of surgeries.

Current Cancer Applications

CANCER APPLICATIONS	PROGRESS
Brain Cancer	• Carl Zeiss Meditec Collaboration – FDA and CE Mark already obtained • Expected sales in first few months of FY20
Oral and Cervical Cancer	• Optiscan seeking FDA and other regulatory approvals for own device* • Expect Carl Zeiss CONVIVO is regulatory precedent as built upon the same technology • Working with Memorial Sloan Kettering – world leading cancer centre (MSK)
Breast Cancer	• Optiscan seeking FDA and other regulatory approvals for own device* • Expect Carl Zeiss CONVIVO is regulatory precedent as built upon the same technology • Trial at Hollywood Private Hospital (Western Australia's largest private hospital) with leading breast cancer surgeon and pathologist
Oesophageal Cancer	• Working with MSK • Previous successful collaboration with Pentax Medical incorporating Optiscan technology in flexible endoscope • Actively seeking collaboration with flexible endoscope manufacturer

*Process and timing in seeking approvals to be determined in conjunction with selected regulatory advisory firm

Brain Cancer – Collaboration with Carl Zeiss Meditec AG





- United States (FDA 510(k)) and European (CE Mark) approvals obtained
- CONVIVO “Digital Biopsy Tool” (Check) an integral part of the 3 step Zeiss Tumour Workflow in Neurosurgery
- Sales expected in first few months of FY20
- https://www.zeiss.com/meditec/int/c/tumor-workflow-video.html

Zeiss is an international leader in the field of optics and optoelectronics with a market capitalisation of ~€7.5billion

Optiscan is Seeking:

- ❑ **510(k) clearance (USA)**
- ❑ **CE Mark (Europe)**
- ❑ **TGA approval (Australia)**

For use of the Optiscan clinical device in human breast, oral and cervical applications*



FDA and other regulatory approvals will significantly broaden the clinical applications for the sale of Optiscan technology into many organ systems

*Process and timing in seeking approvals to be determined in conjunction with selected regulatory advisory firm

Breast Cancer - The Most Common Cancer in Women

2.1 Million	15% of cases	556 centers	145 hospitals
2.1 million new cases of breast cancer predicted in 2018 (globally)[1]	15% of all new cancer cases in the United States are breast cancer[2]	There are 556 Breast Centers in the USA accredited by the US Commission on Cancer[3]	There are 145 hospitals in Australia performing breast cancer surgeries[4]

The number of breast cancer cases and defined cancer centres represent a large target market.
20-30% of lumpectomy patients currently require repeat surgery with current practice (histopathology analysis) often taking up to 3-4 days post initial surgery.

1. GLOBOCAN 2018 estimates; uses Bray et al 2018 paper in CA: A Cancer Journal for Clinicians, page 398 **2**. American Cancer Society Estimated 2019 statistics **3.**https://www.facs.org/search/cancer-programs
4.https://www.myhospitals.gov.au/compare-hospitals/cancer-surgery-waiting-times/breast-cancer

Breast Cancer Clinical Trial

Trial at Hollywood Private Hospital in Perth with Principal Investigators

- Dr Peter Willsher, Breast Surgeon of the Breast Cancer Research Centre –WA
- Dr Jespal Gill, Anatomical Pathologist and Head of Histopathology of Western Diagnostic Pathology
- Dr Philip Currie – Cardiologist, Cardiac Imaging Specialist and Optiscan Director

	Today		
Stage 1 October 2018	Stage 2 June 2019	Stage 3 TBC	Stage 4 TBC
Examination of excised breast tissue specimens by CLE and histopathology	Examination of excised fresh breast tissue specimens	Examination of breast tissue specimens in the operating theatre	Examination of breast tissue specimens in patients

Oral, Cervical and Oesophageal Cancer Applications: Working with Memorial Sloan Kettering Cancer Centre (MSK)

- MSK is the world's oldest and largest private cancer center, situated in New York, USA.
- MSK's use of Optiscan's device provides critical endorsement of its unique imaging capabilities.
- Optiscan is working with MSK for the development of screening, early diagnosis and surgical tools targeting cancer cells in oral, cervical and oesophageal applications.
- MSK is currently seeking approval for use of an Optiscan system in an oral cancer trial. Further approvals are intended to be sought for the cervical and oesophageal cancer trials.
- Presentations by MSK surgeon & research investigator in April 2019 in Melbourne (Peter MacCallum Cancer Centre) and Perth (Hollywood Private Hospital).

Gastrointestinal Applications

- 3.4 Million Gastrointestinal cancer cases world wide
- MSK collaboration for oesophageal (upper GI) application
- Previous successful collaboration with Pentax Medical with over 100 devices sold
- Collaboration ceased following takeover of Pentax Medical
- Pentax systems developed with Optiscan still being used by leading gastroenterologists
- US reimbursement codes already in existence
- Optiscan is actively seeking a new partner in the flexible endoscope market for collaboration in gastrointestinal applications



Optiscan Technology in Pre-clinical Market

Progress in the Preclinical market

- Product re-branded FIVE2 (ViewnVivo)
- Identified opportunities to change existing research techniques for enhanced outcomes
- Multiple trial demonstrations & funding being sought by research institutions for potential purchase in Australia, North America, EU & China
- Working with CSIRO and Monash University for new applications in Cell Cultures and Anterior Cruciate Ligament (ACL) imaging respectively

Research Applications with FIVE2 (ViewnVivo)

- Cancer research
- Tissue regeneration
- Cell tracking
- Photodynamic therapy
- Infection & treatment
- Pharmacology
- Pathology
- Microvascular research
- Animal models
- Molecular Imaging

Key Milestones for the Coming Financial Year

July 2019 — December 2019 — June 2020

1st Half		Full Year	
1	Lodge submissions for FDA and other regulatory approvals for one or more cancer applications	5	MSK commence cervical and oesophageal cancer trials
2	Enter production phase for supply of devices to Carl Zeiss Meditec	6	Establish collaboration with flexible endoscope manufacturer for gastrointestinal applications
3	MSK commence in vivo oral cancer trial	7	Extend breast cancer trial to second medical centre
4	Complete Stage 2 and commence Stage 3 of breast cancer trial	8	Sale of 5+ research and pre-clinical FIVE2 systems

Investment Highlights






- Optiscan is entering into new commercial phase
- Optiscan device enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
- Collaboration with Carl Zeiss Meditech AG for Brain Cancer Surgical Device (US FDA and EU certifications already approved for use) and expected sales in first few months of FY20
- Working with world-leading Memorial Sloan Kettering Cancer Centre in Oral, Cervical and Oesophageal Cancer applications with Oral Cancer trial awaiting internal Ethics Approval to commence
- Seeking US FDA and other regulatory approvals for Optiscan device for Human Oral, Cervical and Breast Cancer applications